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Human cytomegalovirus (CMV) has evolved numerous strategies for evading host immune defenses, includ-
ing piracy of cellular cytokines. A viral homolog of interleukin-10, designated cmvIL-10, binds to the cellular
IL-10 receptor and effects potent immune suppression. The signaling pathways employed by cmvIL-10 were
investigated, and the classic IL-10R/JAK1/Stat3 pathway was found to be activated in monocytes. However,
inhibition of JAK1 had little effect on cmvIL-10-mediated suppression of tumor necrosis factor alpha (TNF-)
production. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway had a more significant impact on
TNF- levels but did not completely relieve the immune suppression, demonstrating that cmvIL-10 stimulates
multiple signaling pathways to modulate cell function.
Human cytomegalovirus (CMV) is a widespread pathogen
that persists as a lifelong latent infection. While infection is
often asymptomatic in healthy individuals, life-threatening dis-
ease may occur in immunocompromised individuals, particu-
larly transplant recipients, AIDS patients, or neonates (9, 11).
The establishment of latency in immune-competent hosts is
enhanced by numerous strategies for avoiding immune clear-
ance (5, 16). Viral gene products US2, US3, US6, and US11
prevent expression of class I major histocompatibility complex
(MHC) molecules on the surface of infected cells, evading
cytotoxic T-lymphocyte detection (1, 2). To minimize natural
killer cell-mediated lysis, an MHC I homolog is expressed
(UL18), and nonclassical MHC molecules are up-regulated by
gpUL40 (3, 31). In addition, HCMV encodes an interleukin-10
(IL-10) homolog, cmvIL-10, which inhibits immune cell prolif-
eration, inflammatory cytokine synthesis, and MHC antigen
expression (30).
Human IL-10 (hIL-10) binds the cellular IL-10 receptor
(IL-10R), engaging tyrosine kinases JAK1 and Tyk2 (23). This
leads to phosphorylation of IL-10R chains and recruitment of
Stats, which become phosphorylated, form homo- or het-
erodimers, and translocate to the nucleus (13, 14, 20, 29).
cmvIL-10 was found to strongly activate Stat3, but not Stat1, in
monocytes. Stat3 phosphorylation occurred at two distinct
sites, Y701 and S727. Suppression of cytokine synthesis by
cmvIL-10 was only minimally affected by inhibiting JAK1 but
was instead found to require phosphatidylinositol 3-kinase
(PI3K) activity.
cmvIL-10 activates Stat3. Previous studies demonstrated
that cmvIL-10 engages the IL-10R (18), resulting in phosphor-
ylation of Stat1 and Stat3 (21). However, these results were
obtained using peripheral blood mononuclear cells, and hIL-10
induces differential activation of Stats in monocytes and T cells
(14). To examine cmvIL-10 signaling in a pure population,
monocytes were isolated from healthy human donors, treated
with hIL-10 or cmvIL-10, and analyzed for the activation of
Stat3. Western blotting revealed that Stat3 became phosphor-
ylated on Y705 after treatment with either cytokine (Fig. 1A).
Polyclonal antiserum directed to Stat3 showed the total
amount of unmodified protein in each lysate and verified equal
sample loading. Lysates were also probed for activation of
Stat1, but no phosphorylation was observed in response to
either hIL-10 or cmvIL-10. Polyclonal antiserum revealed un-
modified Stat1 in the lysate, and treatment with gamma inter-
feron induced phosphorylation of Stat1 at Y701. These results
demonstrate that both cmvIL-10 and hIL-10 stimulate phos-
phorylation of Stat3 in monocytes.
To confirm that cmvIL-10-mediated Stat3 activation re-
quires JAK1, monocytes were pretreated with a JAK1-specific
inhibitor before incubation with cmvIL-10. Stat3 was not phos-
phorylated in cells treated with JAK1 inhibitor (Fig. 1B), while
treatment with MEK1 inhibitor or dimethyl sulfoxide had no
impact on Stat3 phosphorylation. Binding of cmvIL-10 to the
cellular IL-10R leads to JAK1-dependent Stat3 activation;
thus, the viral cytokine employs the same intracellular signaling
pathway as hIL-10.
JAK1 activity is not essential for cmvIL-10-mediated im-
mune suppression. Because JAK1 activity was required for
Stat3 activation, JAK1 was predicted to be necessary for sup-
pression of inflammatory cytokines, a hallmark property of
hIL-10 and cmvIL-10 (12, 30, 32). To investigate this, mono-
cytes were incubated with JAK1 inhibitor prior to treatment
with cmvIL-10 and lipopolysaccharide (LPS), and supernatants
were analyzed for TNF- levels by enzyme-linked immunosor-
bent assay (ELISA). LPS, a strong inflammatory stimulator,
triggered high levels of TNF- (Fig. 2). Treatment with cmvIL-10
reduced TNF- levels by 86%. Unexpectedly, treatment with
JAK1 inhibitor did not cause TNF- levels to rise significantly.
At the highest dose of inhibitor, TNF- levels were still at 65%
of the control LPS level, and only 18% inhibition of cmvIL-10
suppression was observed. While cmvIL-10 activates the JAK1/
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Stat3 pathway, this cascade plays only a minor role in inhibiting
cytokine synthesis in monocytes.
TNF- suppression is sensitive to PI3K inhibition. To
examine other signaling pathways involved in cmvIL-10 im-
mune suppression, various inhibitors were tested for the
ability to restore TNF- production by cmvIL-10-treated
monocytes (Fig. 3A). Treatment with p38 mitogen-activated
protein kinase inhibitor SB20035 resulted in undetectable
levels of TNF- in the presence or absence of cmvIL-10.
Only LY249002 and wortmannin caused increases in TNF-
levels, indicating that PI3K mediates inhibition of cytokine
synthesis by cmvIL-10.
To assess additive or synergistic effects of the two pathways,
monocytes were incubated with JAK1 inhibitor and LY249002 in
combination (Fig. 3B). This treatment did not relieve cmvIL-10
suppression of TNF- any more than PI3K inhibitor alone. These
findings indicate that either JAK1 plays no role in inhibition of
cytokine synthesis or that there may be convergence of the JAK1
and PI3K signaling pathways. If so, the most likely point of con-
vergence would be Stat3, which can be phosphorylated at Y705
and also at a second site, S727 (10, 33).
cmvIL-10 stimulates Akt activation and Stat3 (S727) phos-
phorylation. To further investigate the role of PI3K in cm-
vIL-10 signaling, Akt, a downstream effector of PI3K, was
examined. Treatment of monocytes with cmvIL-10 led to Akt
activation, as evidenced by S473 phosphorylation (Fig. 4).
While JAK1 inhibitor pretreatment did not impact Akt activa-
tion, LY249002 prevented phosphorylation of Akt. Phosphor-
ylation of Stat3 S727 occurred in cmvIL-10-treated monocytes
and was dependent on PI3K, but not on JAK1 activity, indicating
that Stat3 is a common target in both pathways.
Virus persistence is enhanced by viral proteins that manip-
ulate cellular signaling pathways, particularly those that sup-
press immune function, like the IL-10 cascade. Immunoblot-
ting revealed that cmvIL-10 used the same cellular signaling
pathway as hIL-10 and activated Stat3, but not Stat1, via JAK1
in monocytes. While a more sensitive assay might reveal weak
Stat1 activation in cmvIL-10-treated monocytes, it is more
likely that Stat1 activation seen previously in peripheral blood
mononuclear cells occurred in T cells (21). Interestingly, al-
though cmvIL-10 activates Stat3 through JAK1 activity in
monocytes, JAK1 activity was nonessential for inhibition of
TNF- production. This evidence suggests a role for PI3K,
with the most likely scenario being that PI3K activates Akt,
which activates mTOR, which targets Stat3 on S727 (24, 34).
Although the importance of S727 phosphorylation for full tran-
scriptional activity of Stat3 has previously been reported (10,
33), it is noteworthy that phosphorylation at this site alone (in
the absence of Y705 phosphorylation) resulted in significant
changes in cytokine gene expression.
While activation of PI3K by hIL-10 has been well docu-
mented (4, 22, 26, 28, 35), this pathway was thought to be
required for proliferative but not antiinflammatory effects of
the cytokine (8). Treatment with LY249002 consistently in-
creased TNF- relative to the cvmIL-10-suppressed levels,
clearly indicating PI3K is important for this inhibition. The
FIG. 1. cmvIL-10 activates Stat3 but not Stat1 in monocytes. A. Cell
lysates from primary human CD14 monocytes treated with 10 ng/ml
recombinant hIL-10 or cmvIL-10 (R&D Systems) for 10 min were sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
immunoblotted with polyclonal antiserum (Cell Signaling) to detect phos-
phorylated or total unmodified Stat protein as indicated. Monocytes were
isolated from buffy coats of healthy human donors by Ficoll density gra-
dient centrifugation and magnetic separation with anti-CD14 microbeads
(Miltenyi). B. Cells were pretreated with 10 M JAK1 inhibitor {2-(1,1-
dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-
7-one, dissolved in dimethyl sulfoxide; Calbiochem} or MEK1 inhibitor
(U0126; Cell Signaling) for 1 hour prior to treatment with 10 ng/ml
cmvIL-10, and then lysates were immunoblotted. The total protein in each
lysate was quantified (Bio-Rad protein assay kit), and 10 g total protein
was loaded in each well. Results are representative of experiments per-
formed on cells from three different donors.
FIG. 2. Inhibition of TNF- does not require JAK1 activity. Mono-
cytes were incubated with JAK1 inhibitor for 1 h prior to treatment
with 1 ng/ml LPS in the presence or absence of 10 ng/ml cmvIL-10.
After 18 h, supernatants were collected and TNF- levels were de-
tected via sandwich ELISA (R&D Systems). Gray bars, LPS treatment
only; black bars, LPS plus cmvIL-10. Error bars show standard devia-
tions. Statistical analysis was performed using Student’s t test, and
differences in TNF- production between cmv-IL-10-treated and un-
treated monocytes were significant regardless of inhibitor dose. , P 
0.01. Results are representative of experiments performed on cells
from five different donors in 96-well plates with 5  104 cells per well.
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differing results may reflect variations in cell preparation or
treatment protocol but are unlikely to represent a true signal-
ing difference between hIL-10 and cmvIL-10. Similar results
were obtained with each inhibitor using hIL-10-treated mono-
cytes (data not shown), and no significant signaling differences
between hIL-10 and cmvIL-10 have been reported to date (6,
7, 27).
Because none of the inhibitors used here restored TNF- to
control levels, it seems likely that additional signaling mechanisms
still contribute to cmvIL-10-induced suppression. The inhibition
of inflammatory cytokine synthesis by hIL-10 has been reported
to be both Stat3 dependent (29) and independent (25), support-
ing the notion that cmvIL-10 may still exert immunomodulatory
effects through other cellular pathways or receptors. Recent evi-
dence has suggested that LAcmvIL-10, an alternately spliced
form of cmvIL-10 expressed during latency (17), down-modulates
MHC expression independent of IL-10R (15), and a whole family
of IL-10-related receptors have been identified in recent years
FIG. 3. PI3K plays a role in cmvIL-10-mediated cytokine suppression. (A) LPS-stimulated monocytes (1 ng/ml) were incubated with a panel
of different commercially available signal transduction inhibitors [JAK3 inhibitor 4-(4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (Calbio-
chem), MEK1 inhibitor U0126 and PI3K inhibitor LY249002 (Cell Signaling), or wortmannin and p38 mitogen-activated protein kinase inhibitor
SB203580 (Sigma)] in the presence or absence of 10 ng/ml cmvIL-10. Trypan blue analysis confirmed cells from each treatment were viable and
then supernatants were analyzed for TNF- levels by ELISA after 18 h. Gray bars, LPS treatment only; black bars, LPS plus cmvIL-10. Statistical
analysis showed that TNF- levels increased significantly in the presence of cmvIL-10 only with treatment with PI3K inhibitors LY249002 and
wortmannin. , P  0.01, Student’s t test. Results are representative of experiments performed on cells from five different donors. (B) Monocytes
were incubated in the presence of the JAK1 inhibitor (circle), the PI3K inhibitor (LY249002; square), or both inhibitors (triangle) for 1 hour prior
to LPS stimulation in the presence of 10 ng/ml cmvIL-10 and then TNF- levels were measured by ELISA. A single black diamond indicates the
level of TNF- in the presence of LPS only. Results are representative of experiments performed on cells from three different donors. Error bars
represent standard deviations.
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(19). Further investigation will be required to fully understand the
function of cmvIL-10 in virus infection.
This work was supported by NIH grant AI063529 and USF Faculty
Development Funds.
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FIG. 4. cmvIL-10 induces PI3K-dependent phosphorylation of Akt
and Stat3 (S7272). Human monocytes were treated with 50 M JAK1
or PI3K inhibitor (LY249002) for 1 h prior to incubation with 10 ng/ml
cmvIL-10 and then lysates were immunoblotted with polyclonal anti-
serum (Cell Signaling) to phosphorylated or total unmodified Stat3 or
Akt protein. Results are representative of experiments performed on
cells from three different donors.
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